{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:32:33Z","timestamp":1781530353497,"version":"3.54.1"},"reference-count":152,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pancreatic Cancer Action Network-Career Development Award","award":["21-20-JAIN"],"award-info":[{"award-number":["21-20-JAIN"]}]},{"name":"Pancreatic Cancer Action Network-Career Development Award","award":["1R03CA283232-01"],"award-info":[{"award-number":["1R03CA283232-01"]}]},{"DOI":"10.13039\/100000002","name":"NIH\/NCI-RO3","doi-asserted-by":"publisher","award":["21-20-JAIN"],"award-info":[{"award-number":["21-20-JAIN"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH\/NCI-RO3","doi-asserted-by":"publisher","award":["1R03CA283232-01"],"award-info":[{"award-number":["1R03CA283232-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Department of Surgery, Thomas Jefferson University","award":["21-20-JAIN"],"award-info":[{"award-number":["21-20-JAIN"]}]},{"name":"Department of Surgery, Thomas Jefferson University","award":["1R03CA283232-01"],"award-info":[{"award-number":["1R03CA283232-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) is an aggressive solid malignancy with poor overall prognosis and limited response to standard treatments. Growing interest in the modulation of DNA repair mechanisms, including the homologous recombination (HR) repair pathway, has opened new avenues for therapeutic development. BARD1 (BRCA1-Associated RING Domain 1) plays a complex role in tumor biology, functioning either as a tumor suppressor or as an oncogenic driver, depending on isoform expression, cellular context, and regulatory environment. In this review, we examine the dual roles of BARD1, focusing on its regulation and paradoxical activities in PDAC. We summarize evidence that BARD1 and BARD1 isoforms differentially affect DNA repair, apoptosis, and drug resistance and evaluate the therapeutic potential of targeting BARD1 and other DNA damage response (DDR) proteins. We also review ongoing clinical trials and investigational agents designed to exploit DDR vulnerabilities in PDAC. Together, these insights highlight BARD1\u2019s context-dependent roles in PDAC and support continued efforts to profile BARD1 isoforms, clarify their functions, and leverage DDR pathways through precision oncology approaches.<\/jats:p>","DOI":"10.3390\/ijms26189041","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T11:00:00Z","timestamp":1758106800000},"page":"9041","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["BARD1: A Friend or Foe in Pancreatic Ductal Adenocarcinoma?"],"prefix":"10.3390","volume":"26","author":[{"given":"Lily","family":"Zekavat","sequence":"first","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9383-7501","authenticated-orcid":false,"given":"Aditi","family":"Jain","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA"},{"name":"Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic Cancer: A Review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Stoof, J., Harrold, E., Mariottino, S., Lowery, M.A., and Walsh, N. (2021). DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.749490"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","article-title":"Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival","volume":"31","author":"Varghese","year":"2025","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13014-019-1345-6","article-title":"Pancreatic ductal adenocarcinoma: Biological hallmarks, current status, and future perspectives of combined modality treatment approaches","volume":"14","author":"Orth","year":"2019","journal-title":"Radiat. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1002\/jcb.26284","article-title":"Targeted therapies in pancreatic cancer: Promises and failures","volume":"120","author":"Afzaljavan","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"ref_7","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Perkhofer, L., Golan, T., Cuyle, P.J., Matysiak-Budnik, T., Van Laethem, J.L., Macarulla, T., Cauchin, E., Kleger, A., Beutel, A.K., and Gout, J. (2021). Targeting DNA Damage Repair Mechanisms in Pancreas Cancer. Cancers, 13.","DOI":"10.3390\/cancers13174259"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00115","article-title":"Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program","volume":"3","author":"Pishvaian","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_10","first-page":"45","article-title":"Opportunities for translation: Targeting DNA repair pathways in pancreatic cancer","volume":"1846","author":"Maginn","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1053\/j.gastro.2019.02.037","article-title":"Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41580-020-0218-z","article-title":"The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication","volume":"21","author":"Tarsounas","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Prakash, R., Zhang, Y., Feng, W., and Jasin, M. (2015). Homologous recombination and human health: The roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb. Perspect. Biol., 7.","DOI":"10.1101\/cshperspect.a016600"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41586-024-07910-2","article-title":"Promotion of DNA end resection by BRCA1-BARD1 in homologous recombination","volume":"634","author":"Salunkhe","year":"2024","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41586-024-07909-9","article-title":"Mechanism of BRCA1-BARD1 function in DNA end resection and DNA protection","volume":"634","author":"Ceppi","year":"2024","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1016\/j.molcel.2021.05.010","article-title":"Structural insight into BRCA1-BARD1 complex recruitment to damaged chromatin","volume":"81","author":"Dai","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature24060","article-title":"BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing","volume":"550","author":"Zhao","year":"2017","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1038\/s41467-021-25346-4","article-title":"RNF168-mediated localization of BARD1 recruits the BRCA1-PALB2 complex to DNA damage","volume":"12","author":"Krais","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1158\/0008-5472.CAN-22-1535","article-title":"BRCA1-Dependent and Independent Recruitment of PALB2-BRCA2-RAD51 in the DNA Damage Response and Cancer","volume":"82","author":"Foo","year":"2022","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Guo, M., and Wang, S.M. (2022). The BRCAness Landscape of Cancer. Cells, 11.","DOI":"10.3390\/cells11233877"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/ng1296-430","article-title":"Identification of a RING protein that can interact in vivo with the BRCA1 gene product","volume":"14","author":"Wu","year":"1996","journal-title":"Nat. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7706","DOI":"10.1021\/bi700323t","article-title":"Crystal Structure of the BARD1 BRCT Domains","volume":"46","author":"Birrane","year":"2007","journal-title":"Biochemistry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nsb1001-833","article-title":"Structure of a BRCA1-BARD1 heterodimeric RING-RING complex","volume":"8","author":"Brzovic","year":"2001","journal-title":"Nat. Struct. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"11446","DOI":"10.1021\/bi801115g","article-title":"The BARD1 C-terminal domain structure and interactions with polyadenylation factor CstF-50","volume":"47","author":"Edwards","year":"2008","journal-title":"Biochemistry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8855","DOI":"10.1074\/jbc.M413741200","article-title":"Nuclear targeting and cell cycle regulatory function of human BARD1","volume":"280","author":"Schuchner","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1038\/sj.onc.1207302","article-title":"Nuclear-cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1","volume":"23","author":"Rodriguez","year":"2004","journal-title":"Oncogene"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5646","DOI":"10.1073\/pnas.0836054100","article-title":"Binding and recognition in the assembly of an active BRCA1\/BARD1 ubiquitin-ligase complex","volume":"100","author":"Brzovic","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1016\/j.molcel.2023.09.015","article-title":"Crucial roles of the BRCA1-BARD1 E3 ubiquitin ligase activity in homology-directed DNA repair","volume":"83","author":"Wang","year":"2023","journal-title":"Mol. Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"21315","DOI":"10.1074\/jbc.M200769200","article-title":"BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export","volume":"277","author":"Fabbro","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1042\/BCJ20200864","article-title":"The BRCA1\/BARD1 ubiquitin ligase and its substrates","volume":"478","author":"Witus","year":"2021","journal-title":"Biochem. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1073\/pnas.0610887104","article-title":"Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase","volume":"104","author":"Eakin","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100548","DOI":"10.1016\/j.mcpro.2023.100548","article-title":"Ubiquitinome Profiling Reveals in Vivo UBE2D3 Targets and Implicates UBE2D3 in Protein Quality Control","volume":"22","author":"Yalcin","year":"2023","journal-title":"Mol. Cell. Proteom."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1073\/pnas.081068398","article-title":"Cancer-predisposing mutations within the RING domain of BRCA1: Loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity","volume":"98","author":"Ruffner","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6755","DOI":"10.1093\/emboj\/cdf691","article-title":"Activation of the E3 ligase function of the BRCA1\/BARD1 complex by polyubiquitin chains","volume":"21","author":"Mallery","year":"2002","journal-title":"EMBO J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"14537","DOI":"10.1074\/jbc.C000881200","article-title":"The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation","volume":"276","author":"Hashizume","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1128\/MCB.23.14.5056-5063.2003","article-title":"Loss of Bard1, the heterodimeric partner of the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal instability","volume":"23","author":"McCarthy","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.cell.2011.03.035","article-title":"Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression","volume":"145","author":"Brady","year":"2011","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S1097-2765(01)00406-3","article-title":"Identification of BARD1 as mediator between proapoptotic stress and p53-dependent apoptosis","volume":"8","author":"Leung","year":"2001","journal-title":"Mol. Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/sj.onc.1208491","article-title":"BARD1 induces apoptosis by catalysing phosphorylation of p53 by DNA-damage response kinase","volume":"24","author":"Feki","year":"2005","journal-title":"Oncogene"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.yexcr.2004.05.004","article-title":"BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention","volume":"298","author":"Fabbro","year":"2004","journal-title":"Exp. Cell Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.cell.2006.08.053","article-title":"The BRCA1\/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly","volume":"127","author":"Joukov","year":"2006","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1158\/1055-9965.EPI-15-0455","article-title":"Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients","volume":"25","author":"Hu","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/gim.2017.85","article-title":"Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history","volume":"20","author":"Chaffee","year":"2018","journal-title":"Genet. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/hmg\/7.2.195","article-title":"Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers","volume":"7","author":"Thai","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/gcc.1223","article-title":"Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast\/ovarian families negative for BRCA1 and BRCA2 alterations","volume":"33","author":"Ghimenti","year":"2002","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3835(03)00387-2","article-title":"Mutational analysis of BARD1 in familial breast cancer patients in Japan","volume":"200","author":"Ishitobi","year":"2003","journal-title":"Cancer Lett."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1038\/sj.onc.1207427","article-title":"Nuclear-cytoplasmic translocation of BARD1 is linked to its apoptotic activity","volume":"23","author":"Jefford","year":"2004","journal-title":"Oncogene"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.canlet.2005.03.012","article-title":"A truncated splice variant of human BARD1 that lacks the RING finger and ankyrin repeats","volume":"233","author":"Tsuzuki","year":"2006","journal-title":"Cancer Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"34056","DOI":"10.1039\/C8RA06524A","article-title":"Biophysical evaluation to categorize pathogenicity of cancer-predisposing mutations identified in the BARD1 BRCT domain","volume":"8","author":"Choudhary","year":"2018","journal-title":"RSC Adv."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Adamovich, A.I., Banerjee, T., Wingo, M., Duncan, K., Ning, J., Martins Rodrigues, F., Huang, K.L., Lee, C., Chen, F., and Ding, L. (2019). Functional analysis of BARD1 missense variants in homology-directed repair and damage sensitivity. PLoS Genet., 15.","DOI":"10.1371\/journal.pgen.1008049"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nsmb.3236","article-title":"Human BRCA1-BARD1 ubiquitin ligase activity counteracts chromatin barriers to DNA resection","volume":"23","author":"Densham","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41556-019-0282-9","article-title":"H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids","volume":"21","author":"Nakamura","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0092-8674(01)00270-7","article-title":"The BARD1-CstF-50 interaction links mRNA 3\u2032 end formation to DNA damage and tumor suppression","volume":"104","author":"Kleiman","year":"2001","journal-title":"Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ebiom.2017.01.038","article-title":"BARD1 Gene Polymorphisms Confer Nephroblastoma Susceptibility","volume":"16","author":"Fu","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Alshatwi, A.A., Hasan, T.N., Syed, N.A., Shafi, G., and Grace, B.L. (2012). Identification of functional SNPs in BARD1 gene and in silico analysis of damaging SNPs: Based on data procured from dbSNP database. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0043939"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.7150\/jca.36164","article-title":"Functional characterization of full-length BARD1 strengthens its role as a tumor suppressor in neuroblastoma","volume":"11","author":"Cimmino","year":"2020","journal-title":"J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10549-006-9332-7","article-title":"Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain (BARD1) gene are associated with breast cancer susceptibility: A case-control analysis","volume":"102","author":"Huo","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13058-019-1137-9","article-title":"Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer","volume":"21","author":"Borde","year":"2019","journal-title":"Breast Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Randall, M.P., Egolf, L.E., Vaksman, Z., Samanta, M., Tsang, M., Groff, D., Evans, J.P., Rokita, J.L., Layeghifard, M., and Shlien, A. (2023). BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma. bioRxiv.","DOI":"10.1101\/2023.01.31.525066"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41439-024-00267-y","article-title":"BARD1 deletion in a patient with suspected hereditary colorectal cancer","volume":"11","author":"Takaiso","year":"2024","journal-title":"Hum. Genome Var."},{"key":"ref_65","first-page":"2601","article-title":"A Comparative Analysis of Breast and Ovarian Cancer-related Gene Mutations in Canadian and Saudi Arabian Patients with Breast Cancer","volume":"35","author":"Amemiya","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ygyno.2009.05.011","article-title":"Polymorphisms in HPV E6\/E7 protein interacted genes and risk of cervical cancer in Chinese women: A case-control analysis","volume":"114","author":"Zhou","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/jmg.2004.030049","article-title":"Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer","volume":"42","author":"Sauer","year":"2005","journal-title":"J. Med. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Stacey, S.N., Sulem, P., Johannsson, O.T., Helgason, A., Gudmundsson, J., Kostic, J.P., Kristjansson, K., Jonsdottir, T., Sigurdsson, H., and Hrafnkelsson, J. (2006). The BARD1 Cys557Ser variant and breast cancer risk in Iceland. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030217"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"djv214","DOI":"10.1093\/jnci\/djv214","article-title":"Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer","volume":"107","author":"Ramus","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/cge.12620","article-title":"Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients","volume":"89","author":"Desmedt","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"E1175","DOI":"10.1002\/humu.21200","article-title":"Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families","volume":"31","author":"Loris","year":"2010","journal-title":"Hum. Mutat."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Klonowska, K., Ratajska, M., Czubak, K., Kuzniacka, A., Brozek, I., Koczkowska, M., Sniadecki, M., Debniak, J., Wydra, D., and Balut, M. (2015). Analysis of large mutations in BARD1 in patients with breast and\/or ovarian cancer: The Polish population as an example. Sci. Rep., 5.","DOI":"10.1038\/srep10424"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10549-007-9799-x","article-title":"BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer","volume":"111","author":"Gorringe","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12931-015-0278-3","article-title":"BARD1 mediates TGF-beta signaling in pulmonary fibrosis","volume":"16","author":"Andre","year":"2015","journal-title":"Respir. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"24669","DOI":"10.1074\/jbc.M502446200","article-title":"Hyperphosphorylation of the BARD1 tumor suppressor in mitotic cells","volume":"280","author":"Choudhury","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_76","first-page":"1081","article-title":"The post-translational modification, SUMOylation, and cancer (Review)","volume":"52","author":"Han","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1074\/mcp.O114.044792","article-title":"System-wide Analysis of SUMOylation Dynamics in Response to Replication Stress Reveals Novel Small Ubiquitin-like Modified Target Proteins and Acceptor Lysines Relevant for Genome Stability","volume":"14","author":"Xiao","year":"2015","journal-title":"Mol. Cell. Proteom."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nsmb.3366","article-title":"Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation","volume":"24","author":"Hendriks","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1158\/0008-5472.CAN-10-1304","article-title":"HERC2 is an E3 ligase that targets BRCA1 for degradation","volume":"70","author":"Wu","year":"2010","journal-title":"Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bbrc.2014.01.075","article-title":"HUWE1 interacts with BRCA1 and promotes its degradation in the ubiquitin-proteasome pathway","volume":"444","author":"Wang","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"41014","DOI":"10.1074\/jbc.M112.407106","article-title":"The F-box protein FBXO44 mediates BRCA1 ubiquitination and degradation","volume":"287","author":"Lu","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbrc.2022.04.100","article-title":"CRL4-DCAF8L2 E3 ligase promotes ubiquitination and degradation of BARD1","volume":"611","author":"Deng","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.7150\/ijbs.57178","article-title":"CRL4-DCAF8L1 Regulates BRCA1 and BARD1 Protein Stability","volume":"18","author":"Liu","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.molcel.2010.02.038","article-title":"Regulated degradation of spindle assembly factors by the anaphase-promoting complex","volume":"38","author":"Song","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"108921","DOI":"10.1016\/j.celrep.2021.108921","article-title":"SIRT2 promotes BRCA1-BARD1 heterodimerization through deacetylation","volume":"34","author":"Minten","year":"2021","journal-title":"Cell. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/1947601912475079","article-title":"The Roles of SIRT1 in Cancer","volume":"4","author":"Lin","year":"2013","journal-title":"Genes Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Fiorentino, F., Carafa, V., Favale, G., Altucci, L., Mai, A., and Rotili, D. (2021). The Two-Faced Role of SIRT6 in Cancer. Cancers, 13.","DOI":"10.3390\/cancers13051156"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/1947601912473826","article-title":"Emerging Roles of SIRT1 in Cancer Drug Resistance","volume":"4","author":"Wang","year":"2013","journal-title":"Genes Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biocel.2015.12.008","article-title":"New concepts on BARD1: Regulator of BRCA pathways and beyond","volume":"72","author":"Ratajska","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1447-0756.2012.01979.x","article-title":"Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression","volume":"39","author":"Wang","year":"2013","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Zhang, L., and Long, X. (2015). Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies. Sci. Rep., 5.","DOI":"10.1038\/srep17869"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.biocel.2007.04.018","article-title":"Identification of BARD1 splice-isoforms involved in human trophoblast invasion","volume":"39","author":"Li","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Bayraktar, E., Rodriguez, C., Kumar, S., Stur, E., Mangala, L.S., Baylin, S., Lopez-Berestein, G., Pradeep, S., and Sood, A.K. (2023, January 14\u201319). Abstract 6001: Epigenetic regulation of BARD1 confers resistance to anti-VEGF therapy in ovarian cancer. Proceedings of the American Association for Cancer Research Annual Meeting 2023, Orlando, FL, USA.","DOI":"10.1158\/1538-7445.AM2023-6001"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/15592294.2018.1481706","article-title":"Loci-specific differences in blood DNA methylation in HBV-negative populations at risk for hepatocellular carcinoma development","volume":"13","author":"Lubecka","year":"2018","journal-title":"Epigenetics"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Murfuni, I., Basile, G., Subramanyam, S., Malacaria, E., Bignami, M., Spies, M., Franchitto, A., and Pichierri, P. (2013). Survival of the replication checkpoint deficient cells requires MUS81-RAD52 function. PLoS Genet., 9.","DOI":"10.1371\/journal.pgen.1003910"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.1158\/1078-0432.CCR-11-0263","article-title":"BARD1 expression predicts outcome in colon cancer","volume":"17","author":"Sporn","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"McDougall, L.I., Powell, R.M., Ratajska, M., Lynch-Sutherland, C.F., Hossain, S.M., Wiggins, G.A.R., Harazin-Lechowska, A., Cybulska-Stopa, B., Motwani, J., and Macaulay, E.C. (2021). Differential Expression of BARD1 Isoforms in Melanoma. Genes, 12.","DOI":"10.3390\/genes12020320"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Ozden, O., Bishehsari, F., Bauer, J., Park, S.H., Jana, A., Baik, S.H., Sporn, J.C., Staudacher, J.J., Yazici, C., and Krett, N. (2016). Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer. Sci. Rep., 6.","DOI":"10.1038\/srep26273"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.biocel.2009.12.025","article-title":"Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1","volume":"42","author":"Dizin","year":"2010","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Jasiak, A., Krawczynska, N., Iliszko, M., Czarnota, K., Buczkowski, K., Stefanowicz, J., Adamkiewicz-Drozynska, E., Cichosz, G., and Izycka-Swieszewska, E. (2021). Expression of BARD1 beta Isoform in Selected Pediatric Tumors. Genes, 12.","DOI":"10.3390\/genes12020168"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10549-015-3575-0","article-title":"BRCA1 and BARD1 colocalize mainly in the cytoplasm of breast cancer tumors, and their isoforms show differential expression","volume":"153","author":"Wiener","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/ijc.21428","article-title":"Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis","volume":"118","author":"Wu","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/ijc.26346","article-title":"BARD1: An independent predictor of survival in non-small cell lung cancer","volume":"131","author":"Zhang","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1158\/0008-5472.CAN-07-2370","article-title":"Oncogenic BARD1 isoforms expressed in gynecological cancers","volume":"67","author":"Li","year":"2007","journal-title":"Cancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Lepore, I., Dell\u2019Aversana, C., Pilyugin, M., Conte, M., Nebbioso, A., De Bellis, F., Tambaro, F.P., Izzo, T., Garcia-Manero, G., and Ferrara, F. (2013). HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and\/or b. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0083018"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1158\/0008-5472.CAN-11-3703","article-title":"Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity","volume":"72","author":"Bosse","year":"2012","journal-title":"Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/bjc.2012.297","article-title":"Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome","volume":"107","author":"Zhang","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"9339","DOI":"10.18632\/oncotarget.14068","article-title":"Antagonizing functions of BARD1 and its alternatively spliced variant BARD1\u03b4 in telomere stability","volume":"8","author":"Pilyugin","year":"2017","journal-title":"Oncotarget"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.canlet.2016.07.034","article-title":"BARD1 splice variants display mislocalization in breast cancer cells and can alter the apoptotic response to cisplatin","volume":"381","author":"Marzec","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Herrera, C.P., P\u00e9rez, E., Blanco, E., Gajardo, P., and Carvallo, P. (2014, January 5\u20139). Abstract 2455: BRCA1 and BARD1 expression and localization in breast cell lines. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA, USA.","DOI":"10.1158\/1538-7445.AM2014-2455"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.biocel.2014.06.018","article-title":"Long non-coding RNA and microRNAs might act in regulating the expression of BARD1 mRNAs","volume":"54","author":"Pilyugin","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1158\/0008-5472.CAN-23-0972","article-title":"Targeting the RNA-Binding Protein HuR in Cancer","volume":"83","author":"Finan","year":"2023","journal-title":"Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Jain, A., McCoy, M., Coats, C., Brown, S.Z., Addya, S., Pelz, C., Sears, R.C., Yeo, C.J., and Brody, J.R. (2022). HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms. Cancers, 14.","DOI":"10.3390\/cancers14071848"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1038\/onc.2015.325","article-title":"The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells","volume":"35","author":"Blanco","year":"2016","journal-title":"Oncogene"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e1469","DOI":"10.1002\/wrna.1469","article-title":"Complex HuR function in pancreatic cancer cells","volume":"9","author":"Brody","year":"2018","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The MYC oncogene\u2014the grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"101152","DOI":"10.1016\/j.neo.2025.101152","article-title":"Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma","volume":"63","author":"Patel","year":"2025","journal-title":"Neoplasia"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1101\/gad.1897010","article-title":"Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer","volume":"24","author":"Oliver","year":"2010","journal-title":"Genes Dev."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1200\/JCO.2010.34.3616","article-title":"DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy","volume":"29","author":"Wang","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1535-7163.MCT-20-0365","article-title":"Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer","volume":"20","author":"Parsels","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"10593","DOI":"10.2147\/OTT.S254292","article-title":"End Processing Factor APLF Promotes NHEJ Efficiency and Contributes to TMZ- and Ionizing Radiation-Resistance in Glioblastoma Cells","volume":"13","author":"Dong","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Oyama, S., Matsuda, A., Murakami, R., Kakizaki, Y., Ishizawa, T., Kobayashi, T., Nakamura, H., Nawa, Y., Otaki, Y., and Nagata, Y. (2025). Pancreatic cancer organoids derived from EUS-guided fine needle aspiration specimens can be used to predict chemotherapy resistance. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-09395-z"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/MPA.0b013e31821ae25b","article-title":"Increased expression of DNA repair genes in invasive human pancreatic cancer cells","volume":"40","author":"Mathews","year":"2011","journal-title":"Pancreas"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1038\/s41467-018-03951-0","article-title":"Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1","volume":"9","author":"Zhu","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1158\/2326-6066.CIR-18-0683","article-title":"Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer","volume":"7","author":"Gurjao","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Gu, P., Xue, L., Zhao, C., Li, W., Jiang, Z., Liu, A., Li, T., Liu, L., Decker, M., and Cheng, X. (2022). Targeting the Homologous Recombination Pathway in Cancer With a Novel Class of RAD51 Inhibitors. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.885186"},{"key":"ref_128","unstructured":"U.S. Food and Drug Administration (2025, September 10). FDA Approves Lynparza for Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-gbrcam-metastatic-pancreatic-adenocarcinoma."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"S922","DOI":"10.1016\/j.annonc.2024.08.1567","article-title":"1504MO Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum","volume":"35","author":"Park","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_130","unstructured":"(2018). Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination with Olaparib or Durvalumab in Patients with Selected Solid Tumor Malignancies, AstraZeneca."},{"key":"ref_131","unstructured":"(2016). Olaparib for BRCAness Phenotype in Pancreatic Cancer: Phase II Study, National Cancer Institute and AstraZeneca."},{"key":"ref_132","unstructured":"(2015). A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors, AstraZeneca."},{"key":"ref_133","unstructured":"(2019). A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients with Pancreatic Ductal Adenocarcinoma, American Association for Cancer."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"B138","DOI":"10.1158\/1535-7163.TARG-23-B138","article-title":"Abstract B138: Pharmacodynamics-driven phase 2 trial of talazoparib in patients with advanced solid tumors and aberrations in genes involved in DNA damage response","volume":"22","author":"Ko","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"101584","DOI":"10.1016\/j.esmoop.2023.101584","article-title":"Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: Dose-finding results from phase Ib of the JAVELIN PARP MEKi trial","volume":"8","author":"Tan","year":"2023","journal-title":"ESMO Open"},{"key":"ref_136","unstructured":"(2018). Phase 2 Proof-of-Concept Trial Testing the PARP Inhibitor Niraparib in Patients with Pancreatic Cancer Harboring Deficiencies in Homologous Recombination DNA Repair, Tesaro, Inc."},{"key":"ref_137","unstructured":"(2018). Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): A Phase 2 Trial, Tesaro, Inc."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"TPS4161","DOI":"10.1200\/jco.2014.32.15_suppl.tps4161","article-title":"A phase 2, open-label study of rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation","volume":"32","author":"Domchek","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA\/PALB2 Mutation","volume":"38","author":"Lee","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_140","unstructured":"AbbVie (2016). AbbVie Receives FDA Orphan Drug Designation for Investigational Medicine Veliparib for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer, PRNewswire."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/0008-5472.CAN-18-3645","article-title":"Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer","volume":"79","author":"Jain","year":"2019","journal-title":"Cancer Res."},{"key":"ref_142","unstructured":"(2023). A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors, IDEAYA Biosciences."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e2413954121","DOI":"10.1073\/pnas.2413954121","article-title":"PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancer","volume":"121","author":"Ravindranathan","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2022.40.16_suppl.3012","article-title":"NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors","volume":"40","author":"Villaruz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_145","unstructured":"(2020). Phase 1 Trial of Gemcitabine Combined with the Elimusertib (BAY 1895344) ATR Inhibitor with Expansion Cohorts in Advanced Pancreatic and Ovarian Cancer, NCI."},{"key":"ref_146","unstructured":"(2023). Phase 2 Single Arm Trial Testing the ZN-c3 WEE1 Inhibitor in Combination with Gemcitabine in Second-Line Advanced Pancreatic Adenocarcinoma, Lustgarten, F., K-Group, Beta, Inc., Stand Up To Cancer."},{"key":"ref_147","unstructured":"(2023). A Phase 1\/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients with Advanced or Metastatic Solid Tumors, Lantern Pharma, Inc."},{"key":"ref_148","unstructured":"(2024). A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination with a PARP Inhibitor in Participants with Advanced or Metastatic Solid Tumors, MOMA therap."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13046-025-03389-5","article-title":"A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic resistance in pancreatic cancer","volume":"44","author":"Calheiros","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ccr.2013.03.025","article-title":"Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation","volume":"23","author":"Li","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Pilyugin, M., Ratajska, M., Stukan, M., Concin, N., Zeillinger, R., and Irminger-Finger, I. (2021). BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer. Genes, 12.","DOI":"10.3390\/genes12070969"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Pilyugin, M., Descloux, P., Andr\u00e9, P.A., Laszlo, V., Dome, B., Hegedus, B., Sardy, S., Janes, S., Bianco, A., and Laurent, G.J. (2017). BARD1 serum autoantibodies for the detection of lung cancer. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0182356"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/18\/9041\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:46:53Z","timestamp":1760035613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/18\/9041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":152,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijms26189041"],"URL":"https:\/\/doi.org\/10.3390\/ijms26189041","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}